Bli medlem
Bli medlem

Du är här

2016-11-15

DNA Oyj: DNA's Finnish prospectus has been published

DNA OYJ PRESS RELEASE 15 NOVEMBER 2016, 8.00 am EET
DNA's Finnish prospectus has been published

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO
THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH
AFRICA OR SINGAPORE
OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION
WOULD BE UNLAWFUL.
This document is an announcement and not a prospectus for the purposes of
applicable measures implementing EU Directive 2003/71/EC as amended (such
Directive, together with any applicable implementing measures of the relevant
Member State under such Directive, the "Prospectus Directive") and as such
does not constitute an offer to sell or the solicitation of an offer to
purchase securities. Investors should not subscribe for, or purchase, any
securities referred to in this document except on the basis of the
information in the prospectus, prepared pursuant to the Prospectus Directive,
in connection with the proposed listing of ordinary shares in the share
capital of the Company on Nasdaq Helsinki Ltd (the "Prospectus").
DNA Oyj ("DNA" or the "Company") publishes a Finnish language prospectus (the
"Finnish Prospectus") in connection with its planned initial public offering
("IPO" or the "Offering"). The subscription period for the IPO commences
today 15 November 2016 at 10:00 EET.

The Finnish Financial Supervisory Authority has on 14 November approved DNA's
Finnish Prospectus. The Finnish Prospectus relates to the IPO, in which
preliminarily a maximum of 1,000,000 Offer Shares (as defined below) are
being offered to private individuals and entities in Finland and 39,981,143
Offer Shares to Finnish and international institutional investors, assuming
the over-allotment option is not exercised. In the personnel offering, the
Company is offering a maximum of 50,000 New Shares (as defined below) and, in
the event of an oversubscription, a maximum of 250,000 additional New Shares
for subscription to all permanent or fixed-term employees of the Company or
its wholly-owned subsidiaries in Finland and all agency employees who work at
the Company or its wholly-owned subsidiaries in Finland during the
subscription period, the members of the Board of Directors of the Company and
the CEO of the Company (the "Personnel Offering"). The terms and conditions
of the Offering are attached in their entirety to this release.

By offering new shares ("New Shares") for subscription (the "Share Issue"),
the Company aims to raise gross proceeds of approximately EUR 50 million. In
addition, preliminarily up to 35,950,000 existing shares (the "Sale Shares",
and together with the New Shares, the "Offer Shares") in the Company are
being offered for sale by certain existing shareholders of the Company. The
number of New Shares to be issued will be determined based on the final offer
price per Offer Share (the "Final Offer Price"), which will be communicated
through a stock exchange release on or about 29 November 2016. The Company
would issue 4,766,905 New Shares assuming that the Final Offer Price would be
at the mid-point of the preliminary price range of EUR 9.85 - 11.15 per Offer
Share and total of 50,000 New Shares would be subscribed in the Personnel
Offering at a discount applicable to such New Shares. In the event the number
of New Shares issued in the Share Issue is 4,766,905 as mentioned above, the
number of Company's shares outstanding after the Offering would amount to
132,092,755 shares.

DNA announced the preliminary price range for the IPO on 14 November 2016. The
Finnish Prospectus and a Finnish-language marketing brochure are available in
electronic format on the Company's website at www.dna.fi/listautumisanti. An
English-language Offering Circular (the "Offering Circular") can be found in
electronic format on the Company's website atwww.dna.fi/ipo. In addition,
printed versions of the Finnish Prospectus, marketing brochure and the
Offering Circular are expected to be available no later than 17 November 2016
and can be obtained at the Company's headquarters (Läkkisepäntie 21, 00620
Helsinki), offices of Danske Bank and Nordea as well as at the Helsinki Stock
Exchange (Fabianinkatu 14, 00100 Helsinki).

Further information on the IPO, including places of subscription, can be
obtained fromwww.dna.fi/listautumisanti, www.danskebank.fi,www.nordea.fiand
from the branch offices of Danske Bank and Nordea.

Further enquiries

Jukka Leinonen, CEO, DNA Oyj, tel. +358 44 044 1000,jukka.leinonen@dna.fi

DNA Corporate Communications, tel. +358 44 044 8000,communications@dna.fi

Disclaimer

The information contained herein does not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of the securities
referred to herein in any jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration, exemption from registration or
qualification under the securities laws of any jurisdiction.

This document is not an offer for sale nor a solicitation of an offer to buy
any securities in the United States (including any of its states, its
territories and possessions and the District of Columbia). These materials
are not for distribution, directly or indirectly, in or into the United
States. The securities referred to herein (the "Securities") have not been
and will not be registered under the U.S. Securities Act of 1933, as amended
(the "Securities Act"), or the laws of any state of the United States.
Consequently, the Securities may not be offered, sold, pledged or otherwise
transferred directly or indirectly in or into the United States except in
accordance with the registration requirements of the Securities Act or an
exemption therefrom. No public offering of the Securities is being made in
the United States.

This document is an announcement and not a prospectus for the purposes of
applicable measures implementing EU Directive 2003/71/EC as amended (such
Directive, together with any applicable implementing measures of the relevant
Member State under such Directive, the "Prospectus Directive") and as such
does not constitute an offer to sell or the solicitation of an offer to
purchase securities. Investors should not subscribe for, or purchase, any
securities referred to in this document except on the basis of the
information in the prospectus, prepared pursuant to the Prospectus Directive,
in connection with the proposed listing of ordinary shares in the share
capital of the Company on Nasdaq Helsinki Ltd (the "Prospectus"), which will
be approved by the Finnish Financial Supervisory Authority and published in
due course.

A prospectus prepared pursuant to the Prospectus Directive and the Finnish
Securities Markets Act (746/2012, as amended) on the public offering of
securities and the admission of securities to trading on a regulated market
(the "Prospectus Law") will be approved by the Finnish Financial Supervisory
Authority and published which, when published, will be made available in
accordance with the requirements of the Prospectus Directive and the
Prospectus Law in Finland and can be obtained from the Company and other
placed indicated in the Prospectus.

The securities referred to herein are not and will not be publicly offered,
sold or registered, in any jurisdiction other than Finland. Any offer of
securities to the public that may be deemed to be made pursuant to this
communication in any EEA Member State other than Finland is addressed solely
to qualified investors (within the meaning of the Prospectus Directive) in
that Member State.

The joint global coordinators and the joint bookrunners are each acting
exclusively for the Company and for no-one else in connection with any
transaction mentioned in this announcement and will not regard any other
person (whether or not a recipient of this announcement) as a client in
relation to any such transaction and will not be responsible to any other
person for providing the protections afforded to their respective clients, or
for advising any such person on the contents of this announcement or in
connection with any transaction referred to in this announcement. The
contents of this announcement have not been verified by the joint global
coordinators or joint bookrunners.

This announcement does not constitute a recommendation concerning the
offering. The price and value of securities and any income from them can go
down as well as up. Past performance is not a guide to future performance.
Information in this announcement or any of the documents relating to the
offering cannot be relied upon as a guide to future performance. There is no
guarantee that the listing on the Helsinki Stock Exchange will occur and you
should not base your financial decisions on the Company's intentions in
relation to the listing at this stage. Potential investors should consult a
professional advisor as to the suitability of the offering for the entity
concerned.

Each of the joint global coordinators and joint bookrunners and any of their
respective affiliates, acting as investors for their own accounts, may
purchase shares and in that capacity may retain, purchase, sell, offer to
sell or otherwise deal for their own accounts in such shares and other
securities of the Company or related investments in connection with the
offering or otherwise. Accordingly, references in the final prospectus, once
published, to the shares being offered, acquired, sold, placed or otherwise
dealt in should be read as including any offer, sale, acquisition, placing or
dealing in the shares by any of the joint global coordinators and joint
bookrunners and any of their affiliates acting as investors for their own
accounts. In addition, certain of the joint global coordinators or joint
bookrunners or their affiliates may enter into financing arrangements and
swaps in connection with which they or their affiliates may from time to time
acquire, hold or dispose of shares. None of the joint global coordinators or
joint bookrunners intends to disclose the extent of any such investment or
transaction otherwise than in accordance with any legal or regulatory
obligations to do so.

No representation or warranty, express or implied, is given by or on behalf of
the joint global coordinators or joint bookrunners or any of their respective
subsidiaries, affiliates, agents or advisers or any of such persons'
affiliates, directors, officers or employees or any other person as to the
fairness, truth, accuracy, completeness or verification of the information or
the opinions contained in this announcement (or whether any information has
been omitted from the announcement) or any other information relating to the
Company, its subsidiaries or associated companies, whether written, oral or
in a visual or electronic form, and howsoever transmitted or made available,
and no liability is accepted for any such information, omissions or opinions.
Each of the...

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.